190 likes | 609 Views
BDR Pharmaceuticals Int’l Pvt. Ltd. Adding Years To Life & Life To Years. BDR Pharmaceuticals Int’l Pvt. Ltd. Vision. To become strategic innovator & enhance society by endow with innovative products & medical services at affordable prices in life saving category.
E N D
BDR Pharmaceuticals Int’l Pvt. Ltd. Adding Years To Life & Life To Years....
BDR Pharmaceuticals Int’l Pvt. Ltd. Vision To become strategic innovator & enhance society by endow with innovative products & medical services at affordable prices in life saving category.
BDR Pharmaceuticals Int’l Pvt. Ltd. Mission Early identification of newer molecules for life threatening disease that leads us to advance development & introduction of products through the strength of backward integration of developing & manufacturing API’s to facilitate Humankinds.
BDR Pharmaceuticals Int’l Pvt. Ltd. • BDR Pharma has reached excellence in development & marketing • of newer APIs & Formulations. • Core strength lies in identification of newer molecules, development • and commercialization. • BDR offers widest range of finish formulations like : • Lyophilized injectables • Pegylated Liposomal & Oncology products • Gynecology and Higher range Antibiotics
GROWTH MAP • Established in year 2003. • Diversified into API manufacturing in 2005 and consolidated position • in domestic market for the API Business. • Leading Niche specialty player in domestic formulation business from year 2006. • Expanded to have two API facilities at Gujarat and 2 formulation • facilities at Gujarat and Uttarakhand. • Commencing of World class, state of art F & D centre and formulation • manufacturing facility with an aim to augment our presence in the • growing global Oncology Market.
STRATEGIC ROADMAP • Focusing on Non-Infringing process preparation of DMF’s as per ICH, US FDA • guidelines with respect to API. • Backward integration of manufacturing API leads to command on price advantage • Developing and concentrating on High growth therapy areas like Oncology, • Gynecology, Cardiology, High end antibiotics. • Successfully launched products like Edaravone, Citicoline , Bivalirudin, • Bortezomib, Pemetrexed, Gefitinib , Pegylated Liposomal Doxorubicin…..etc.
INNOVATION IN TECHNOLOGIES • New APIs and new process design and development • New catalysts and applications • Stereo-and region-specific reactions by employing immobilized • reagents and catalysts • Semi-synthetic APIs • Industrial chromatography design and application • Process patents underway: Telmisartan, Etoricoxib, Iron Sucrose, • Ranolazine, Adapalene, Nebivolol.
MARKET PRESENCE • One of the Leading Domestic player for Finish Formulation and API’s. • Global Market reach extended beyond 80 countries • Direct presence in Global markets like : Brazil, Argentina, Cuba, DR, Russia, • Sri Lanka and South East Asia etc…. • More then 40 products under registration globally and another 20 in pipeline. • Key partnership with few of the largest API players in Latin America, • South East Asia and CIS for contract manufacturing and licensing.
MANUFACTURING CAPABILITIES • API Manufacturing facilities : Surat and Baroda • 2 Facilities manufactures several APIs in various segments such as NSAIDs, • Antibacterial, Antihypertensives, Cardiac care, Antiosteoperetics, Antiepileptics, • Hematinic, Antihyperlipoproteinemics besides a few others. • Finished Formulation Facilities : Surendranagar and Dehradun • 2 facilities covering Tablets, Capsules, Injectables, Oinments, Syrups.
REGULATORY STATUS • Concurrent up gradation for finished formulation facilities to get MCC (South Africa), • MHRA (UK ), TGA (Australia) and US FDA. • Expertise in compilation of dossiers in CTD formats. • DMF Available for various API’s.
MARKETING ALLIANCE • Product Licensing with long term supply agreements • Distribution and Marketing Tie-ups for Niche products • Technology transfer arrangements • Development of CTD Dossiers
API – EXPERTISE IN HANDLING REACTION • FRIEDAL-CRAFT ACYLATION / ALKYLATION • OXIDATIONS (H2O2 / Cr2O3 / DICHROMATE) • BROMINATION • ANNULATION • HYDROLYSIS • CONDENSATION (ALKYLATION) • CRYSCOPIC REACTION ( - 80°C) • AMINATION • GRIGNARD REACTION • .
API – EXPERTISE IN HANDLING REACTION • SULPHONYL CHLORINATION • ALKYLATIONS • REDUCTIONS / PRESSURE HYDROGENATION • NITRATION • ACETYLATION • HYDRO BROMINATION • HYDRO CHLORINATION • N-BUTYL LITHIUM REACTIONS • Na-METAL REACTION • .
API – AVAILABLE • BASE CATALYSED ALKYLATION • PRESSURE RECTIONS (MAXIMUM UP TO 10 Kg/cm2) • DIAZOTISATION • CYNATION • AZIDE FORMATION • DEBENZYLATION • ESTERIFICATION • DIARYL COUPLING • DECARBOXYLATION • SWERN OXIDATION • CHIRAL SEPARATION • COLUMN CHROMATOGRAPHIC SEPARATION (INDUSTRIAL SCALE) • .
OVERSEAS TIE-UP & CORPORATE OFFICE • . • Delta Biotech, Argentina : Prostaglandins, Deltanoids • Amega Biotech, Argentina : Anti Cancer and Life saving products. Corporate HQ: BDR Pharmaceuticals International PVT. LTD. 407/408 Sharda Chambers, 15 New Marine lines, Mumbai-400020. India Telephone: 0091-22-40560560 (30 Lines) Fax: 0091-22-40560555 Regional Office: Surat / Baroda / Ahmadabad